Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

Embark Behavioral Health, Clinical Social Work/Therapist, Chandler, AZ, 85226, (623) 343-6129, Our therapists are committed to providing your family with the most accessible online therapy to help ...

Embark Behavioral Health operates an exceptional network of treatment and therapy programs across the United States. We specialize in preteens, teens, and young adults, struggling with anxiety ...

Encouraging long-term outcomes were seen in patients with Duchenne muscular dystrophy (DMD) who received the gene therapy delandistrogene moxeparvovec (Elevidys; Sarepta) in the EMBARK trial ...

Cybin Inc., a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced the ...

The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years in patients with Duchenne muscular dystrophy (DMD).

One of Embark Behavioral Health’s newest programs brings 24-hour residential treatment to teens in Greeley and surrounding communities. As a network of clinics and programs, Embark Behavioral Health ...

CAMBRIDGE, Mass., May 16, 2025--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data from Part 2 of the EMBARK study that ...

Published data from EMBARK subsequently confirmed that while the gene therapy missed its primary endpoint, it showed small ...

The FDA is investigating the deaths of two boys with Duchenne muscular dystrophy who died soon after being treated with ...

About EMBARK, Study SRP-9001-301. Study SRP-9001-301, also known as EMBARK, is a multinational, phase 3, randomized, two-part crossover, placebo-controlled study of ELEVIDYS in individuals with ...